BOSTON, Jan. 5 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated. HBV affects over 2 billion people in the world today while HCV affects approximately 4 million people each year. Strategic Research Institute announces the “2nd Annual Viral Hepatitis Drug Discovery & Development Summit” scheduled to take place February 27-28, 2006 in Boston, MA
By attending this industrial and networking conference you will be able to interact with many of the leading research scientists and decision-makers from the pharmaceutical/biotech industry, public health, and academic communities working in the area of viral hepatitis of North America and internationally. The conference will focus primarily on Hepatitis C Virus and Hepatitis B Virus topics. Some of the topics covered include nucleoside and non-nucleoside polymerase inhibitors, protease inhibitors, other antiviral initiatives such as direct antiviral and immune approaches, HCV vaccines, etc.
To request a copy of the conference agenda, please contact the conference organizer Glenn Pascual of Strategic Research Institute at gpascual@srinstitute.com or 212.967.0095, ext. 245. Please include full contact information
To become a media partner, please contact Cheryl-Kahan Radhuber at ckahan-radhuber@srinstitute.com
For more information on sponsorship & exhibition opportunities, please contact Glenn Pascual at gpascual@srinstitute.com
Strategic Research Institute
CONTACT: Glenn Pascual, +1-212-967-0095, ext. 245,gpascual@srinstitute.com, or Cheryl-Kahan Radhuber,ckahan-radhuber@srinstitute.com, both of Strategic Research Institute
Web site: http://www.srinstitute.com/
